Advances in Cardiovascular Science: From Discovery to Translation

Dr. Jörg Taubel, CEO of Richmond Pharmacology, will be attending the Basic Cardiovascular Sciences (BCVS) Scientific Sessions 2024,held from 22nd to 25th July in Chicago, Illinois.

This event features cutting-edge research and advancements in cardiovascular science, including topics like cardiac gene and cell therapy, tissue engineering, and cardiac metabolism.

Attendees will include basic cardiovascular scientists, molecular and cellular biologists, translational investigators, clinical trialists, and practicing cardiologists.

To connect with Dr. Taubel during the event, please reach out to arrange a meeting.

To find out more, click here.

Latest news

Richmond supports Beam Therapeutics to make significant step forward in potential one-time gene editing treatment for Alpha-1

March 30, 2026
Beam Therapeutics has announced compelling updated clinical data from its ongoing Phase 1/2 Trial of BEAM-302 as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD).
Read more

Events

Clinical Trials Innovation Programme

10 - 11 February 2026
Richmond Pharmacology is pleased to attend the Clinical Trials Innovation Programme Conference in Nice, France, 10–11 February 2026.
View event